{"id":38178,"date":"2024-04-03T15:59:47","date_gmt":"2024-04-03T13:59:47","guid":{"rendered":"https:\/\/www.ablehumanmotion.com\/able-partners-with-femm-to-conduct-a-clinical-trial-with-multiple-sclerosis-patients-in-madrid\/"},"modified":"2024-08-07T10:06:47","modified_gmt":"2024-08-07T08:06:47","slug":"able-partners-with-femm-to-conduct-a-clinical-trial-with-multiple-sclerosis-patients-in-madrid__trashed","status":"publish","type":"post","link":"https:\/\/www.ablehumanmotion.com\/en\/able-partners-with-femm-to-conduct-a-clinical-trial-with-multiple-sclerosis-patients-in-madrid__trashed\/","title":{"rendered":"ABLE partners with FEMM to conduct a Clinical Trial with Multiple Sclerosis patients in Madrid"},"content":{"rendered":"

We are thrilled to announce a groundbreaking partnership between ABLE Human Motion and Fundaci\u00f3n Esclerosis M\u00faltiple Madrid (FEMM) to initiate a new clinical trial to validate the ABLE Exoskeleton in people affected by multiple sclerosis (MS). This collaboration marks a significant step forward in our commitment to enabling mobility for everyone, opening the doors for a new indication for our product beyond spinal cord injury.<\/span><\/p>\n

\"\"<\/p>\n

The clinical trial will focus on assessing the impact of gait training with the ABLE Exoskeleton among MS patients on mobility-related outcomes, including<\/span> walking and balance function, <\/span>gait speed, endurance, and functional independence.<\/span><\/p>\n

Other outcomes<\/span> such as general health status, quality of life, and user satisfaction will also be investigated during the trial<\/span>. Individuals diagnosed with multiple sclerosis, aged 18-65 years, who experience mobility limitations and meet predefined inclusion criteria, will be eligible to participate in the trial. <\/span>Participants will undergo a 10-session training program with the ABLE Exoskeleton device for a maximum duration of 11 weeks. <\/span>Data collection will be conducted at multiple time points throughout the trial, including a baseline and post-intervention assessment. This longitudinal approach will enable researchers to track changes in mobility and functional outcomes over time, providing valuable insights into the durability of treatment effects.<\/span><\/p>\n\n

This study represents a milestone in our journey towards enhancing mobility and quality of life for individuals living with neurological impairments. Together, with the expertise of FEMM and the dedication of our team, through interdisciplinary collaboration and scientific excellence, we aim to uncover new insights into the efficacy and potential benefits of exoskeleton-assisted therapy to empower individuals with multiple sclerosis to lead fuller, more independent lives.<\/span><\/p>\n

\"\"<\/p>\n

Detailed information on this exciting clinical trial that will be conducted at Fundaci\u00f3n Esclerosis M\u00faltiple Madrid can be found in the following link: <\/span>https:\/\/clinicaltrials.gov\/study\/NCT06261541?term=ABLE%20Exoskeleton&rank=4<\/span><\/a>\u00a0<\/span><\/p>\n

Recruitment is starting in April 2024<\/strong>. If you have multiple sclerosis, are living in Madrid,<\/strong> and would like to participate in the trial, please contact the Principal Investigator:<\/strong> Almudena Chao, by email <\/span>achao@femmadrid.org<\/span><\/p>\n

Your support and participation are crucial to the success of this investigation. We are grateful for your continued trust in the innovative rehabilitation technologies developed at ABLE Human Motion.<\/span><\/p>\n

Stay tuned for updates as we embark on this exciting journey towards advancing neurorehabilitation and improving the lives of countless individuals worldwide.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

We are thrilled to announce a groundbreaking partnership between ABLE Human Motion and Fundaci\u00f3n Esclerosis M\u00faltiple Madrid (FEMM) to initiate a new clinical trial to validate the ABLE Exoskeleton in people affected by multiple sclerosis (MS). This collaboration marks a significant step forward in our commitment to enabling mobility for everyone, opening the doors for […]<\/p>\n","protected":false},"author":5,"featured_media":37932,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55],"tags":[],"class_list":["post-38178","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-able-exoesqueleto"],"_links":{"self":[{"href":"https:\/\/www.ablehumanmotion.com\/en\/wp-json\/wp\/v2\/posts\/38178","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ablehumanmotion.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ablehumanmotion.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ablehumanmotion.com\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ablehumanmotion.com\/en\/wp-json\/wp\/v2\/comments?post=38178"}],"version-history":[{"count":1,"href":"https:\/\/www.ablehumanmotion.com\/en\/wp-json\/wp\/v2\/posts\/38178\/revisions"}],"predecessor-version":[{"id":39750,"href":"https:\/\/www.ablehumanmotion.com\/en\/wp-json\/wp\/v2\/posts\/38178\/revisions\/39750"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ablehumanmotion.com\/en\/wp-json\/wp\/v2\/media\/37932"}],"wp:attachment":[{"href":"https:\/\/www.ablehumanmotion.com\/en\/wp-json\/wp\/v2\/media?parent=38178"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ablehumanmotion.com\/en\/wp-json\/wp\/v2\/categories?post=38178"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ablehumanmotion.com\/en\/wp-json\/wp\/v2\/tags?post=38178"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}